Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–61 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: omalizumab placebo Clear all
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT03280550
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Roseville, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

NCT01292473
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Placebo, Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
La Jolla, California • Los Angeles, California • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

NCT04180488
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 80 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314
View directory record Official record
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

NCT00890162
View directory record Official record
Conditions
Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions
Epinephrine, Omalizumab (Xolair), Placebos
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 5, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

NCT06934200
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

NCT00078195
View directory record Official record
Conditions
Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions
omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Rhinovirus (strain 16)
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria

NCT02814630
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Xolair
Biological
Lead sponsor
Asthma Inc Clinical Research Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

NCT00870584
View directory record Official record
Conditions
Persistent Allergic Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 5, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 5, 2026, 4:50 AM EDT